Munich Cluster for Systems Neurology

Breadcrumb Navigation


Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.

Neurotherapeutics. 2022 Mar 14. doi: 10.1007/s13311-022-01214-x. Epub ahead of print. PMID: 35289375.

Authors/Editors: Havla J, Hohlfeld R.
Publication Date: 2022


Progressive multiple sclerosis (PMS) is clinically distinct from relapsing-remitting MS (RRMS). In PMS, clinical disability progression occurs independently of relapse activity. Furthermore, there is increasing evidence that the pathological mechanisms of PMS and RRMS are different. Current therapeutic options for the treatment of PMS remain inadequate, although ocrelizumab, a B-cell-depleting antibody, is now available as the first approved therapeutic option for primary progressive MS. Recent advances in understanding the pathophysiology of PMS provide hope for new innovative therapeutic options: these include antibody therapies with anti-inflammatory, neuroprotective, and/or remyelination-fostering effects. In this review, we summarize the relevant trial data relating to antibody therapy and consider future antibody options for treating PMS.


Related Links